钠-葡萄糖共转运蛋白2抑制剂显著降低2型糖尿病患者心脏电生理平衡指数。

IF 0.6
Emrah Özdemir, Murat Ziyrek, Esra Dönmez, Sevgi Özcan, Orhan İnce, Ceyla Zeynep Çolakoğlu Gevher, Bahar Özdemir, Ertuğrul Okuyan
{"title":"钠-葡萄糖共转运蛋白2抑制剂显著降低2型糖尿病患者心脏电生理平衡指数。","authors":"Emrah Özdemir, Murat Ziyrek, Esra Dönmez, Sevgi Özcan, Orhan İnce, Ceyla Zeynep Çolakoğlu Gevher, Bahar Özdemir, Ertuğrul Okuyan","doi":"10.5543/tkda.2024.07280","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Sodium-glucose cotransporter 2 (SGLT2) inhibitors, a novel group of oral antidiabetic drugs, have demonstrated cardioprotective benefits and positive metabolic effects in patients with diabetes mellitus (DM). The cardiac electrophysiological balance index (ICEB) is an eletrocardiographic ratio that provides information about the equilibrium between left ventricular depolarization and repolarization duration, offering valuable insights into the predisposition to ventricular arrhythmias. The aim of this study is to analyze the potential impact of SGLT2 inhibitors on ICEB.</p><p><strong>Method: </strong>Patients were prospectively selected from a pool of 2,789 consecutive type 2 DM patients. After exclusions, 174 patients formed the monotherapy group, and 143 age- and sex-matched patients who were switched to SGLT2 inhibitor combination therapy constituted the combination therapy group. All treatment changes were supervised by endocrinologists blinded to the patient groups. Baseline and six-month electrocardiogram (ECG) data of both groups were analyzed. ICEB was defined as QT/QRS, and ICEBc as QTc/QRS.</p><p><strong>Results: </strong>Although there was no statistically significant difference between the monotherapy and combination therapy groups in terms of baseline ECG parameters, QT (385.05 +- 13.21 vs. 372.32 +- 4.32; P < 0.001), QTc (409.24 +- 8.17 vs. 383.72 +- 7.24; P < 0.001), ICEB (4.15 +- 0.51 vs. 4.03 +- 0.54; P = 0.004), and ICEBc (4.40 +- 0.75 vs. 4.16 +- 0.61; P < 0.0001) values at the six-month mark were significantly lower in the SGLT2 inhibitor group.</p><p><strong>Conclusion: </strong>SGLT2 inhibitors significantly lower ICEB and ICEBc, potentially reducing ventricular susceptibility to arrhythmias as early as six months into treatment for diabetic patients.</p>","PeriodicalId":94261,"journal":{"name":"Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir","volume":"53 2","pages":"113-119"},"PeriodicalIF":0.6000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Sodium-Glucose Cotransporter 2 Inhibitors Significantly Lower the Cardiac Electrophysiological Balance Index in Type 2 Diabetes Patients.\",\"authors\":\"Emrah Özdemir, Murat Ziyrek, Esra Dönmez, Sevgi Özcan, Orhan İnce, Ceyla Zeynep Çolakoğlu Gevher, Bahar Özdemir, Ertuğrul Okuyan\",\"doi\":\"10.5543/tkda.2024.07280\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>Sodium-glucose cotransporter 2 (SGLT2) inhibitors, a novel group of oral antidiabetic drugs, have demonstrated cardioprotective benefits and positive metabolic effects in patients with diabetes mellitus (DM). The cardiac electrophysiological balance index (ICEB) is an eletrocardiographic ratio that provides information about the equilibrium between left ventricular depolarization and repolarization duration, offering valuable insights into the predisposition to ventricular arrhythmias. The aim of this study is to analyze the potential impact of SGLT2 inhibitors on ICEB.</p><p><strong>Method: </strong>Patients were prospectively selected from a pool of 2,789 consecutive type 2 DM patients. After exclusions, 174 patients formed the monotherapy group, and 143 age- and sex-matched patients who were switched to SGLT2 inhibitor combination therapy constituted the combination therapy group. All treatment changes were supervised by endocrinologists blinded to the patient groups. Baseline and six-month electrocardiogram (ECG) data of both groups were analyzed. ICEB was defined as QT/QRS, and ICEBc as QTc/QRS.</p><p><strong>Results: </strong>Although there was no statistically significant difference between the monotherapy and combination therapy groups in terms of baseline ECG parameters, QT (385.05 +- 13.21 vs. 372.32 +- 4.32; P < 0.001), QTc (409.24 +- 8.17 vs. 383.72 +- 7.24; P < 0.001), ICEB (4.15 +- 0.51 vs. 4.03 +- 0.54; P = 0.004), and ICEBc (4.40 +- 0.75 vs. 4.16 +- 0.61; P < 0.0001) values at the six-month mark were significantly lower in the SGLT2 inhibitor group.</p><p><strong>Conclusion: </strong>SGLT2 inhibitors significantly lower ICEB and ICEBc, potentially reducing ventricular susceptibility to arrhythmias as early as six months into treatment for diabetic patients.</p>\",\"PeriodicalId\":94261,\"journal\":{\"name\":\"Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir\",\"volume\":\"53 2\",\"pages\":\"113-119\"},\"PeriodicalIF\":0.6000,\"publicationDate\":\"2025-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5543/tkda.2024.07280\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5543/tkda.2024.07280","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

目的:钠-葡萄糖共转运蛋白2 (SGLT2)抑制剂是一类新型的口服降糖药,在糖尿病(DM)患者中具有心脏保护作用和积极的代谢作用。心脏电生理平衡指数(ICEB)是一种心电图比值,提供左心室去极化和复极化持续时间之间的平衡信息,为室性心律失常的易感性提供有价值的见解。本研究的目的是分析SGLT2抑制剂对ICEB的潜在影响。方法:前瞻性地从2,789例连续2型糖尿病患者中选择患者。排除后,174例患者为单药组,143例年龄和性别匹配的患者改用SGLT2抑制剂联合治疗为联合治疗组。所有的治疗变化都由对患者组不知情的内分泌学家监督。分析两组患者基线及6个月心电图(ECG)数据。ICEB定义为QT/QRS, ICEBc定义为QTc/QRS。结果:虽然单药组与联合治疗组在基线心电图参数方面无统计学差异,但QT (385.05 +- 13.21 vs. 372.32 +- 4.32;P < 0.001), QTc (409.24 +- 8.17 vs 383.72 +- 7.24;P < 0.001), icb (4.15 +- 0.51 vs. 4.03 +- 0.54;P = 0.004)和ICEBc (4.40 +- 0.75 vs. 4.16 +- 0.61;P < 0.0001) 6个月时,SGLT2抑制剂组的数值显著降低。结论:SGLT2抑制剂可显著降低ICEB和ICEBc,可能在糖尿病患者治疗6个月后降低室性心律失常的易感性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Sodium-Glucose Cotransporter 2 Inhibitors Significantly Lower the Cardiac Electrophysiological Balance Index in Type 2 Diabetes Patients.

Objective: Sodium-glucose cotransporter 2 (SGLT2) inhibitors, a novel group of oral antidiabetic drugs, have demonstrated cardioprotective benefits and positive metabolic effects in patients with diabetes mellitus (DM). The cardiac electrophysiological balance index (ICEB) is an eletrocardiographic ratio that provides information about the equilibrium between left ventricular depolarization and repolarization duration, offering valuable insights into the predisposition to ventricular arrhythmias. The aim of this study is to analyze the potential impact of SGLT2 inhibitors on ICEB.

Method: Patients were prospectively selected from a pool of 2,789 consecutive type 2 DM patients. After exclusions, 174 patients formed the monotherapy group, and 143 age- and sex-matched patients who were switched to SGLT2 inhibitor combination therapy constituted the combination therapy group. All treatment changes were supervised by endocrinologists blinded to the patient groups. Baseline and six-month electrocardiogram (ECG) data of both groups were analyzed. ICEB was defined as QT/QRS, and ICEBc as QTc/QRS.

Results: Although there was no statistically significant difference between the monotherapy and combination therapy groups in terms of baseline ECG parameters, QT (385.05 +- 13.21 vs. 372.32 +- 4.32; P < 0.001), QTc (409.24 +- 8.17 vs. 383.72 +- 7.24; P < 0.001), ICEB (4.15 +- 0.51 vs. 4.03 +- 0.54; P = 0.004), and ICEBc (4.40 +- 0.75 vs. 4.16 +- 0.61; P < 0.0001) values at the six-month mark were significantly lower in the SGLT2 inhibitor group.

Conclusion: SGLT2 inhibitors significantly lower ICEB and ICEBc, potentially reducing ventricular susceptibility to arrhythmias as early as six months into treatment for diabetic patients.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信